Loading provider…
Loading provider…
Hematology & Oncology Physician in New York, NY
NPI: 1316926330Primary Practice Location
Manhattan Hematology Oncology Assoc, PC
157 E 32nd St, New York, NY
Primary Employer
Manhattan Hematology Oncology Assoc, PC
mhony.com
HQ Phone
Get MD Alec's Phone Numberphone_androidMobile
Get MD Alec's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardNY State Medical License
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 542 | 3,105 |
| 2 | 36415Insertion of needle into vein for collection of blood sample | 502 | 3,165 |
| 3 | 85025Complete blood cell count (red cells, white blood cell, platelets), automated test | 502 | 3,163 |
| 4 | 99213Established patient office or other outpatient visit, typically 15 minutes | 117 | 668 |
| 5 | 99215Established patient office or other outpatient, visit typically 40 minutes | 114 | 115 |
Chronic thalidomide and chemoembolization for hepatocellular carcinoma.
Authors: Joseph Sparano
Publication Date: 2014-11-02
Sorafenib use for recurrent hepatocellular cancer after resection or transplantation: Observations from a US regional analysis of the GIDEON registry.
Authors: Parvez Mantry, Brendan Mcguire, Allen Cohn, Pierre Gholam
Publication Date: 2016-03-16
Use of Transarterial Chemoembolization (TACE) and Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: US Regional Analysis of the GIDEON Registry.
Authors: Parvez Mantry, Joanne Imperial, Jean-Francois Geschwind, Allen Cohn, Pierre Gholam
Publication Date: 2016-03-19
Lead Sponsor: Aptose Biosciences Inc.
Intervention / Treatment: DRUG: CG-806
Lead Sponsor: Oncternal Therapeutics, Inc
Collaborators: University of California, San Diego, California Institute for Regenerative Medicine (CIRM), Pharmacyclics LLC.
Intervention / Treatment: DRUG: Ibrutinib alone, DRUG: Cirmtuzumab (2-16 kg/mg) plus Ibrutinib, DRUG: Cirmtuzumab (300mg) plus Ibrutinib, DRUG: Cirmtuzumab (600 mg) plus ibrutinib, DRUG: Cirmtuzumab (RDR) plus ibrutinib, DRUG: Cirmtuzumab plus ibrutinib